Our results indicate that targeting ERBB3 in colorectal cancer using monoclonal antibodies, that are currently under development [13], may target differentiated cells and contribute to the elimination of the tumour bulk but may not affect the proliferative cancer stem-like cell population. This evidence concerns the gene ERBB3 and neoplasm.